|
1
|
Wild S, Roglic G, Green A, Sicree R and
King H: Global prevalence of diabetes: Estimates for the year 2000
and projections for 2030. Diabetes Care. 27:1047–1053. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coughlan MT, Cooper ME and Forbes JM:
Renal microvascular injury in diabetes: RAGE and redox signaling.
Antioxid Redox Signl. 9:331–342. 2007. View Article : Google Scholar
|
|
3
|
Battisti WP, Palmisano J and Keane WE:
Dyslipidemia in patients with type 2 diabetes. Relationships
between lipids, kidney disease and cardiovascular disease. Clin
Chem Lab Med. 41:1174–1181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bergrem H and Leivestad T: Diabetic
nephropathy and end-stage renal failure: The Norwegian story. Adv
Ren Replace Ther. 8:4–12. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kolset SO, Reinholt FP and Jenssen T:
Diabetic nephropathy and extracellular matrix. J Histochem
Cytochem. 60:976–986. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu R, Mao J, Yang Y, Zhang Y, Tian Y and
Zhu J: Protective effects of calcitriol on diabetic nephropathy are
mediated by down regulation of TGF-β1 and CIP4 in diabetic
nephropathy rat. Int J Clin Exp Pathol. 8:3503–3512.
2015.PubMed/NCBI
|
|
7
|
Al-Rasheed NM, Al-Rasheed NM, Al-Amin MA,
Hasan IH, Al-Ajmi HN, Mohammad RN and Attia HA: Fenofibrate
attenuates diabetic nephropathy in experimental diabetic rat's
model via suppression of augmented TGF-β1/Smad3 Signaling pathway.
Arch Physiol Biochem. 122:186–194. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sato M, Muragaki Y, Saika S, Roberts AB
and Ooshima A: Targeted disruption of TGF-beta1/Smad3 signaling
protects against renal tubulointerstitial fibrosis induced by
unilateral ureteral obstruction. J Clin Invest. 112:1486–1494.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
State Pharmacopoeia Commission.
Pharmacopoeia of the People's Republic of China. 2005
editionBeijing: Chemical Industry Press; 2005. pp. 212. 2005
|
|
10
|
Wu HW, Fang J, Tang LY, Lu P, Xu H, Zhao
Y, Li D, Zhang Y, Fu M and Yang H: Quality evaluation of Astragali
radix based on DPPH radical scavenging activity and chemical
analysis. Chin Herbal Med. 6:282–289. 2014. View Article : Google Scholar
|
|
11
|
He JX, Mou QQ, Zhang JQ, Tian Q, He C, Yin
R and Li H: Rapid identification of Astragali radix from different
origins by UPLC combined with chemometrics methods. Chin
Traditional Herbal Drugs. 48:179–184. 2017.
|
|
12
|
Yan MM, Wei L, Fu YJ, Zu YG, Chen CY and
Luo M: Optimisation of the microwave-assisted extraction process
for four main astragalosides in radix Astragali. Food Chem.
119:1663–1670. 2010. View Article : Google Scholar
|
|
13
|
Ren S, Zhang H, Mu Y, Sun M and Liu P:
Pharmacological effects of Astragaloside IV: A literature review. J
Tradit Chin Med. 33:413–416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang WD, Chen H, Zhang C, Liu RH, Li HL
and Chen HZ: Astragaloside IV from Astragalus membranaceus
shows cardioprotection during myocardial ischemia in vivo and in
vitro. Planta Med. 72:4–8. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu H, Wei W, Sun WY and Li X: Protective
effects of astragaloside IV on porcine-serum-induced hepatic
fibrosis in rats and in vitro effects on hepatic stellate cells. J
Ethnopharmacol. 122:502–508. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yuan X, Gong Z, Wang B, Guo X, Yang L, Li
D and Zhang Y: Astragaloside inhibits hepatic fibrosis by
modulation of TGF-β1/Smad signaling pathway. Evid Based Complement
Alternat Med. 2018:32316472018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye J, Coulouris G, Zaretskaya I,
Cutcutache I, Rozen S and Madden T: Primer-BLAST: A tool to design
target-specific primers for polymerase chain reaction. BMC
Bioinformatics. 13:1342012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shivananjappa MM and Muralidhara:
Abrogation of maternal and fetal oxidative stress in the
streptozotocin-induced diabetic rat by dietary supplements of
Tinospora cordifolia. Nutrition. 28:581–587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun XY and Sun FY: Shen Nong Ben Cao
JingTaiyuan: Shanxi Science and Technology Press; pp. 112–113.
2010
|
|
21
|
He Y, Du M, Gao Y, Liu H, Wang H, Wu X and
Wang Z: Astragaloside IV Attenuates experimental autoimmune
encephalomyelitis of mice by counteracting oxidative stress at
multiple levels. PLoS One. 8:e764952013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang ZS, Xiong F, Xie XH, Chen D, Pan JH
and Cheng L: Astragaloside IV attenuates proteinuria in
streptozotocin-induced diabetic nephropathy via the inhibition of
endoplasmic reticulum stress. BMC Nephrol. 16:442015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang N, Wang XH, Mao SL and Zhao F:
Astragaloside IV improves metabolic syndrome and endothelium
dysfunction in Fructose-fed rats. Molecules. 16:3896–3907. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang D, Zhang G, Chen X, Wei T, Liu C,
Chen C, Gong Y and Wei Q: Sitagliptin ameliorates diabetic
nephropathy by blocking TGF-β1/Smad signaling pathway. Int J Mol
Med. 41:2784–2792. 2018.PubMed/NCBI
|
|
25
|
Kalluri R and Neilson EG:
Epithelial-mesenchymal transition and its implications for
fibrosis. J Clin Invest. 112:1776–1784. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Izumi N, Mizuguchi S, Inagaki Y, Saika S,
Kawada N, Nakajima Y, Inoue K, Suehiro S, Friedman SL and Ikeda K:
BMP-7 opposes TGF-beta 1-mediated collagen induction in mouse
pulmonary myofibroblasts through Id2. Am J Physiol Lung Cell Mol
Physiol. 290:L120–L126. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li J, Qu X and Bertram JF:
Endothelial-myofibroblast transition contributes to the early
development of diabetic renal interstitial fibrosis in
streptozotocin-induced diabetic mice. Am J Pathol. 175:1380–1388.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma X, Lu C, Lv C, Wu C and Wang Q: The
expression of miR-192 and its significance in diabetic nephropathy
patients with different urine albumin creatinine ratio. J Diabetes
Res. 2016:67894022016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu F, Zhang ZP, Xin GD, Guo LH, Jiang Q
and Wang ZX: miR-192 prevents renal tubulointerstitial fibrosis in
diabetic nephropathy by targeting Egr1. Eur Rev Med Pharmacol Sci.
22:4252–4260. 2018.PubMed/NCBI
|
|
30
|
Wang B, Herman-Edelstein M, Koh P, Burns
W, Jandeleit-Dahm K, Watson A, Saleem M, Goodall GJ, Twigg SM,
Cooper ME and Kantharidis P: E-cadherin expression is regulated by
miR-192/215 by a mechanism that is independent of the profibrotic
effects of transforming growth factor-beta. Diabetes. 59:1794–1802.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chung AC, Huang XR, Meng X and Lan HY:
miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc
Nephrol. 21:1317–1325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kato M, Zhang J, Wang M, Lanting L, Yuan
H, Rossi JJ and Natarajan R: MicroRNA-192 in diabetic kidney
glomeruli and its function in TGF-beta-induced collagen expression
via inhibition of E-box repressors. Proc Natl Acad Sci USA.
104:3432–3437. 2007. View Article : Google Scholar : PubMed/NCBI
|
